Canada markets close in 5 hours 14 minutes

Atossa Therapeutics, Inc. (ATOS)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.7550-0.0228 (-2.93%)
As of 10:44AM EST. Market open.
Full screen
Loading interactive chart...
  • GlobeNewswire

    Atossa Therapeutics Announces Full Enrollment of Phase 2 Karisma-Endoxifen Clinical Trial

    SEATTLE, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer, today announced that it has reached full enrollment in the Company’s Karisma-Endoxifen clinical trial, the 240-person Phase 2 study investigating (Z)-endoxifen in premenopausal women with measurable mammographic breast density (MBD). Participants have be

  • GlobeNewswire

    Atossa Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update

    Achieved significant enrollment milestones in ongoing Phase 2 clinical trialsFour ongoing Phase 2 studies evaluating (Z)-endoxifen, including recently announced study in DCIS Ended third quarter 2023 with $94.0 million of cash and cash equivalents SEATTLE, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative proprietary medicines to address significant unmet needs in oncology with a focus on breast cancer, to

  • GlobeNewswire

    Atossa Therapeutics Appoints Financial Executive Jonathan Finn to its Board of Directors

    SEATTLE, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer, today announced that Jonathan Finn, CFA, has been appointed to Atossa’s board of directors, effective November 8, 2023. Mr. Finn has more than 25 years of experience in the financial industry with a focus on early to mid-stage biotech and technology comp